1. Introduction {#sec1}
===============

Otitis media is a middle ear pathology that includes a wide range of inflammatory diseases, such as otitis media with effusion, chronic suppurative otitis media with and without cholesteatoma and adhesive otitis media. In chronic suppurative otitis media (CSOM), a tympanic membrane (TM) perforation with persistent drainage from the middle ear is the most common pathology ([@bib18]). One of the treatments is a surgical repair by placing an underlay support material medial to the TM. This is done after refreshing the edges of the perforation to activate healing and migration of the epithelial layer. Multiple substances have been used as a scaffold in the treatment of TM perforation such as temporalis muscle fascia, perichondrium, cartilage, fat, and spongostan (haemostatic gel foam). Although the rates of closures after the initial attempt are not bad ([@bib13]), there is a continuous search for new materials that are more effective in the healing of these TM perforations. Among these, the amniotic membrane could be of interest since it contains stem cells which are endowed with anti-inflammatory, anti-infective and immuno-modulatory properties ([@bib5]). However, prior to launching human clinical trials to test new materials, a preclinical study is needed using animal models of chronic TM perforation.

Preclinical studies have been performed so far in animal models of TM perforation which involve laser myringotomy and treatment with hydrocortisone or mitomycin C ([@bib8]; [@bib16]; [@bib9]), but laser equipment is not a common tool in research centers. Therefore, we aimed to develop a new model to create a chronic tympanic membrane perforation (CTMP) by myringotomy and instillation of mitomycin C. Previous methods to create a CTMP without a laser equipment, such as amputation of the handle of the malleus and the application of substances such as dexamethasone ([@bib9]; [@bib21]), have not obtained conclusive results. Thus, the main objective of the present paper was to identify whether incisional myringotomy with the application of mitomycin C alone or in combination with dexamethasone may produce a chronic tympanic perforation model in rats. As a secondary objective, we have analyzed whether the amputation of the handle of the malleus with application of mitomycin C before or after incisional myringotomy could influence the duration of tympanic membrane perforation patency in rats.

2. Materials and methods {#sec2}
========================

All the research was conducted in the Centre for Experimentation and Biomedical Research (CEIB) of the Universidad de Murcia (Murcia, Spain). All experiments and procedures were approved by the local ethics committee and followed the ethical principles and current legislation on protection of animals for research ([@bib12]; [@bib3]; [@bib4]). The study was performed in 34 healthy male Sprague Dawley rats of 8 weeks of age and weights ranging from 310 to 370 g. The environmental conditions were kept constant throughout the study with cycles of 12 h of light and darkness, a constant temperature of 20 °C and a humidity of 48% ([@bib2]). The animals were anesthetized with a mixture of ketamine (40--90 mg/kg, ip) and Xylazine (5--10 mg/kg) ([@bib19]).

To study the patency of a perforation and the influence of different agents in creating a chronic perforation we used two substances: mitomycin C and dexamethasone. Mitomycin C is an aminoglycoside antibiotic that has been used as a cytostatic due to its ability to disrupt DNA replication, inhibiting mitosis, and protein synthesis, thus preventing the replication of fibroblast and epithelial cells and eventually prolonging the healing time ([@bib10]). Dexamethasone is a classical steroid anti-inflammatory drug that inhibits the production of collagen from fibroblasts. The group of controls rats was treated with a 0.9% saline solution.

2.1. Experimental procedure {#sec2.1}
---------------------------

Procedures were performed under direct vision with a Zeiss microscope (Germany) with TM photographs being acquired with a digital camera (Canon Power Shot Pro 1, Japan) attached to a 0° and 3 mm diameter rigid endoscope via an adaptor (GAES audio test HD) and a Karl Storz cold light source, model 482 (Germany). The surgical instruments consisted of a 4 mm diameter ear speculum, a Hartman clip and a Tympanoplasty set (blunt and sharp straight needle, and a small Rosen ring) as shown in [Fig. 1](#fig1){ref-type="fig"}. All myringotomies (size of 2.4 × 2.4 mm) were performed in the pars tensa using a sharp punch, amputating the eardrum handle with the same instrument and extracting the bone fragment with a Hartman clip. The concentration of mitomycin C was 0.4 mg/ml and the time of instillation of mitomycin and 0.9% saline solution was always of 10 min.Fig. 1Camera with optical adapter (right) and tympanoplasty instruments used (left).Fig. 1

Rats were checked afterwards to assess the state of healing of the tympanic perforations at days 3, 7, 10, 14 and weekly thereafter until perforation closure, for up to 6 months. The perforations were measured with a small Rosen ring (0.8 mm diameter). The date of the complete closure of the perforation was obtained by averaging the last day that the perforation was seen and the first day that it was found to be closed. The amount of anesthesia was 0.7 ml of ketamine-Xylazine mixture in the first intervention and 0.4 ml in the revision days. Photographs of the eardrums were taken at every intervention and in revisions. Mitomycin C was applied to the TM on spongostan that had been soaked in it (0.4 mg/ml). Dexamethasone (4 mg/ml) was applied directly in drops given through the external auditory canal until fully filling the middle and the external ear.

The statistical analysis was performed using the software R Core Team 2015 ([@bib11]), by using an ANOVA test and a p value lower than 0.05 was considered to express a significant difference.

2.2. Experimental groups {#sec2.2}
------------------------

A total of 34 rats were used in the present study. They were divided into three groups (A, B and C) to compare the different interventions and their results ([Table 1](#tbl1){ref-type="table"}). In summary, in group A (n = 10), all rats were treated with amputation of the hammer handle. Those of subgroup A1 with application of mitomycin C and subgroup A2 with saline. In all of them, mitomycin or saline was applied after performing myringotomy and amputation of the hammer handle. In group B (n = 12), mitomycin C or saline was applied, according to the subgroups, before performing myringotomy. In subgroup B1, mitomycin was applied before myringotomy without amputating the handle of the hammer. In subgroup B2, mitomycin was applied before myringotomy and the hammer handle was amputated. And in subgroups B3 and B4, saline was applied before the myringotomies. Finally, in group C (n = 12), we proceeded similarly as in group B, but in addition to mitomycin C, dexamethasone was also applied.Table 1Experimental groups.Table 1GroupsnSubgroupsNumber of Eardrums1st intervention2nd intervention3rd interventionA10A110 Left earsMyringotomy + HHAMitomycin CA210 Right earsMyringotomy + HHASaline solutionB12B110 Alternate earsMitomycin CMyringotomyB210 Alternate earsMitomycin CMyringotomy + HHAB32 Alternate earsSaline solutionMyringotomyB42 Alternate earsSaline solutionMyringotomy + HHAC14C110 Alternate earsMitomycin CMyringotomyDexamethasoneC210 Alternate earsMitomycin CMyringotomy + HHADexamethasoneC32 Alternate earsSaline solutionMyringotomySaline solutionC42 Alternate earsSaline solutionMyringotomy + HHASaline solution[^1]

3. Results {#sec3}
==========

Myringotomies treated with saline solution ([Table 2](#tbl2){ref-type="table"}) had a mean healing time of 8.5 days. In group C3, one ear healed at 8.5 days and the other one, at 5 days. Those treated with mitomycin C with or without dexamethasone are shown in [Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}. In subgroup C1, at 8 weeks, there were 8 ears under study, of which 5 were perforated (62.5%). In subgroup C2, at 8 weeks, there were 9 ears in the study, of which 7 remained perforated (77.7%). At 6 months, 12% remained perforated in C1 and 22% in C2 ([Fig. 3](#fig3){ref-type="fig"}). [Fig. 3](#fig3){ref-type="fig"} shows the healing results of the eardrums treated with mitomycin C alone (A1, B1 and B2) and with mitomycin C plus dexamethasone (C1 and C2). Only the ears of group C remain perforated at 8 weeks and 3 eardrums (1 of subgroup C1 and 2 of subgroup C2) remain open for 6 months ([Fig. 4](#fig4){ref-type="fig"}). [Fig. 5](#fig5){ref-type="fig"} shows the duration of tympanic perforations of the ears treated with saline (subgroups A2, B3, B4, C3 and C4) that healed before day 10.Table 2Tympanic permeability duration in myringotomies treated with saline solution.Table 2SubgroupsNumber of eardrumsTreatmentPermeability (days)A210Saline solution8.5B32Saline solution8.5B42Saline solution8.5C32Saline solution8.5 (n = 1), 5.0 (n = 1)C42Saline solution8.5Table 3Tympanic permeability duration in myringotomies treated with Mitomycin C.Table 3SubgroupsTreatmentNumber of eardrumsPermeability (days)Unhealed\
Myringotomies at 6 monthsMean permeability by subgroups (days)Discarded eardrumsMean permeability by groups (days)A1Miringotomy + HHA + Mitomycin C8\
212.0\
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2\
18.5\
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1\
1\
1\
145.5\
52.5\
136.5\
150.5\
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2 Otorrhea[^2]Fig. 2Perforated eardrums of groups A, B and C at 8 weeks.Fig. 2Fig. 3Healing time of tympanic membranes treated with mitomycin C.Fig. 3Fig. 4Perforated eardrums at 6 months (one of subgroup C1 (left image) and two of C2).Fig. 4Fig. 5Healing time of tympanic membranes treated with saline solution.Fig. 5

Laterality (the influence of treating the right or the left ear of the rat) did not significantly affect healing time (p \> 0.6). With regard to healing time, the comparison of subgroups A1 and B2 did not show a significant difference when mitomycin C was applied before or after myringotomy (p \> 0.8). We subsequently compared groups A1 and A2, showing a significant prolongation of the healing time with mitomycin C compared to saline (p \< 0.03). There were significant differences (p \< 0.001) when comparing the eardrums treated only with Mitomycin C (group B, subgroups B1 and B2) with the eardrums treated with Mitomycin C plus Dexametasone (group C, subgroups C1 and C2). No significant differences were found between the amputation of the hammer handles (B2) and myringotomy without amputation (B1). There were also no differences between the subgroups with (C2) or without amputation (C1). Finally, a significant difference (p \< 0.006) was also observed between the eardrums treated with Mitomycin C plus Dexamethasone (groups C1 and C2) and those treated with saline (C3 and C4).

4. Discussion {#sec4}
=============

The tympanic membrane perforations in experimental animals are considered chronic when they are maintained open between 8 and 15 weeks ([@bib14]). Since the 1990s, numerous studies have attempted to establish an animal model of chronic TM perforations using different animals and substances. [@bib20] performed a review of the literature and, out of 37 studies, only 23 of them were able to achieve chronic TM perforations. The chinchilla was the animal most commonly used in these studies, followed by the rat and guinea pig. In our study, we used Sprague Dawley rats because they were easy to handle and have eardrums with histological characteristics similar to humans ([@bib15]).

Also we decided to use a dose of 0.4 mg/ml of mitomycin C. This was based in the study of [@bib8] that compared mitomycin doses of 0.2, 0.4 and 2 mg/ml showing that at 8 weeks 50% of myringotomies treated with 0.4 mg/ml remained patent. [@bib1] recommended the use of gel foam soaked in mitomycin C. These authors performed a comparative study between the direct application of mitomycin C and application with a gel foam, evaluating the toxicity by measuring auditory brainstem responses. The application with gel foam completely prevented toxicity, justifying its use.

Strem et al. ([@bib17]) conducted a study in 60 rats, producing myringotomies by laser and mitomycin C at a concentration of 2 mg/ml. They established several groups with different times of application of mitomycin C and concluded that the patency rate did not improve with an application longer than 10 min nor by repeating the dose. In the study by [@bib6] on the effects of mitomycin C in tympanic membrane fibroblasts in vitro, using different concentrations and times of exposure, the lowest fibroblasts viability was obtained when applying mitomycin C for 10 min at a concentration of 0.4 mg/ml. According to these studies, we applied mitomycin C by spongostan at a concentration of 0.4 mg/ml for 10 min.

Our data shows that the addition of dexamethasone to mitomycin C treatment prolongs the patency rate of myringotomies. These results agree with those of Kaftan H et al. ([@bib21]) in a rat model in which they used mitomycin C at a concentration of 2 mg/ml applied for 10 min before producing the tympanic perforation. In the revisions, they applied dexamethasone at a concentration of 4 mg/ml, with a mean patency of the perforation of 17.5 days when they used mitomycin C alone and 32 days when associated with dexamethasone. In our study we obtained a similar average patency of 15.1 days when treating rats with myringotomies after application of mitomycin C alone (group B), while in Group C (application of mitomycin C and dexamethasone) we obtained an average permeability of 112.7 days, significantly higher than that achieved by Kaftan et al. ([@bib21]). However, these authors ([@bib21]) used a mitomycin C concentration 5 times greater than the concentration recommended, which we used. Previously published studies of incisional myringotomy with mitomycin C did not succeed in obtaining enough chronic tympanic membrane perforations. Only the laser myringotomy associated with mitomycin C treatment was able to produce chronic perforations ([@bib7]). However, the laser technology is not available to the majority of experimental laboratories.

Recent studies by [@bib22] have used a similar method although they obtained perforations of insufficient duration to establish and constitute a chronicity model. The difference is probably related to the method used since these authors employed a higher dose of mitomycin, different from the one recommended in the [@bib8] work. Another important difference, in our opinion, is the application of dexamethasone, which they applied only once. We think that the application of dexamethasone in every revision is essential to succeed with the chronic lesion.

5. Conclusion {#sec5}
=============

In this study, we have established a rat model of chronic tympanic membrane perforation by combining mitomycin C (0.4 mg/ml for 10 min) prior to incisional myringotomy and adding dexamethasone (4 mg/ml) on four additional doses. The addition of dexamethasone to mitomycin C is a key component for obtaining a good rate of tympanic opening in this experimental animal model. Our technique is able to maintain, between 62 and 77% of tympanic membrane perforations created by incisional myringotomy and mitomycin C treatment, patent for at least 8 weeks. This model performed in Sprague Dawley rats is robust, reproducible and convenient for preclinical as well as translational research of this pathology.
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[^1]: HHA: Hammer handle amputation.

[^2]: HHA: Hammer handle amputation.
